Literature DB >> 17003820

Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors.

S K Rakowski1, E B Winterkorn, E Paul, D J R Steele, E F Halpern, E A Thiele.   

Abstract

Tuberous sclerosis complex is a genetic disorder characterized by hamartomatous lesions in multiple organs, frequently involving the kidney. We conducted a retrospective review of the clinical and radiographic records of 167 patients with tuberous sclerosis to determine the frequency of renal disease, the likelihood of significant renal morbidity, and the effects of genotype (TSC1 vs TSC2) and gender on renal phenotype. Renal lesions were seen in 57.5% of patients. Of these, angiomyolipoma (AML) occurred in 85.4%, cysts in 44.8%, and renal cell carcinoma in 4.2%. Both AML and cysts were significantly more common and more numerous in TSC2 than in TSC1. AML was significantly more common in female than in male patients, but cysts showed no correlation with gender. Eleven patients developed renal abnormalities during their care in this practice at an average age of onset of 11.3 years (range 3.8-23 years). The frequency and number of renal lesions were positively correlated with age. Interventions, including arterial embolization and nephrectomy, were performed in 11 (6.6%) patients. Among female patients with lymphangioleiomyomatosis, renal AML was universally present. Our findings confirm a high rate of renal involvement; a low rate of serious complications; significant associations between renal involvement, genotype, and gender; and a significant association between renal and pulmonary involvement in female patients.

Entities:  

Mesh:

Year:  2006        PMID: 17003820     DOI: 10.1038/sj.ki.5001853

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  110 in total

Review 1.  Tuberous sclerosis complex renal disease.

Authors:  Bradley P Dixon; John C Hulbert; John J Bissler
Journal:  Nephron Exp Nephrol       Date:  2010-11-11

2.  Association between the growth rate of renal cysts/angiomyolipomas and age in the patients with tuberous sclerosis complex.

Authors:  Jeng-Dau Tsai; Chang-Ching Wei; Shan-Ming Chen; Ko-Huang Lue; Ji-Nan Sheu
Journal:  Int Urol Nephrol       Date:  2014-03-30       Impact factor: 2.370

3.  Composite renal cell carcinoma and angiomyolipoma in a patient with Tuberous sclerosis: A diagnostic dilemma.

Authors:  Aanchal Kakkar; Archana George Vallonthaiel; Mehar Chand Sharma; Girdhar Bora; Ananya Panda; Amlesh Seth
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 4.  Tuberous sclerosis complex: new insights into clinical and therapeutic approach.

Authors:  Angela Volpi; Gabriele Sala; Elena Lesma; Francesca Labriola; Marco Righetti; Rosa Maria Alfano; Mario Cozzolino
Journal:  J Nephrol       Date:  2018-11-07       Impact factor: 3.902

Review 5.  An approach to cystic kidney diseases: the clinician's view.

Authors:  Christine E Kurschat; Roman-Ulrich Müller; Mareike Franke; David Maintz; Bernhard Schermer; Thomas Benzing
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

6.  Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex.

Authors:  Àlex Rovira; María Luz Ruiz-Falcó; Elena García-Esparza; Eduardo López-Laso; Alfons Macaya; Ignacio Málaga; Élida Vázquez; Josefina Vicente
Journal:  J Neurooncol       Date:  2014-04-27       Impact factor: 4.130

Review 7.  Thoracoabdominal imaging of tuberous sclerosis.

Authors:  Cara E Morin; Nicholas P Morin; David N Franz; Darcy A Krueger; Andrew T Trout; Alexander J Towbin
Journal:  Pediatr Radiol       Date:  2018-08-04

8.  Polycystic kidney disease and chronic renal failure in tuberous sclerosis.

Authors:  Mona Dhakal; O P Dhakal; Dhurba Bhandari
Journal:  BMJ Case Rep       Date:  2013-10-02

Review 9.  Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.

Authors:  Ken Inoki; Kun-Liang Guan
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 10.  Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.

Authors:  Ruirong Yuan; Andrea Kay; William J Berg; David Lebwohl
Journal:  J Hematol Oncol       Date:  2009-10-27       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.